Praveen Kumar Marimuthu

Employment

• Christian Medical College, Vellore Assistant Professor
  2025 - Present
• Christian Medical College, Vellore Senior Resident
  2022 - 2025
• Harshamitra Super-Specialty Cancer Center and Research Institute Junior Consultant
  2019 - 2021

Education

• HCG Cancer Hospital DNB (Radiation Oncology)
  2016 - 2019
• Sree Mookambika Institute of Medical Sciences MBBS
  2008 - 2014
• Christian Medical College, Vellore DM Medical Oncology

Projects & Funding

Projects & funding information is unavailable.

Publications (27)

• Early palliative care integration in advanced cancer: two institutional quality improvement projects
  BMJ Supportive & Palliative Care 2026 DOI: 10.1136/spcare-2025-005644
  +Save
• Unfinished Frock
  JCO Global Oncology 2026 DOI: 10.1200/GO-25-00621
  +Save
• A Randomized Study Comparing the Efficacy of Erector Spinae Block vs Parenteral Analgesia Post Operatively in Patients Undergoing Laparoscopic Abdominal Surgery
  Indian Journal of Surgery 2026 DOI: 10.1007/S12262-026-04582-2
  +Save
• A two-step pre-treatment screening strategy combining enzyme phenotyping and targeted DPYD genotyping: A pragmatic approach for preventing fluoropyrimidine toxicity
  Journal of Clinical Oncology 2026 DOI: 10.1200/JCO.2026.44.19_SUPPL.306
  +Save
• Neoadjuvant chemoimmunotherapy before chemoradiation vs chemoradiation alone for stage IIB-IIIC1 carcinoma of the cervix: A phase II open-label randomized controlled trial (NeoCHIMERA)
  Journal of Clinical Oncology 2026 DOI: 10.1200/JCO.2026.44.16_SUPPL.TPS5631
  +Save
• Real world outcomes with neoadjuvant chemo-immuno-metronomic therapy in advanced head and neck squamous cell carcinoma (NeoLOCUS-Retro)
  Journal of Clinical Oncology 2026 DOI: 10.1200/JCO.2026.44.19_SUPPL.236
  +Save
• Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
  The Lancet Regional Health - Southeast Asia 2026 DOI: 10.1016/j.lansea.2026.100743
  +Save
• Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis
  JCO Global Oncology 2025 DOI: 10.1200/GO-24-00256
  +Save
• Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy
  Scientific Reports 2025 DOI: 10.1038/S41598-025-19197-Y
  +Save
• Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for "borderline resectable" oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
  Annals of Oncology 2024 DOI: 10.1016/J.ANNONC.2024.08.924
  +Save